Inhibition of insulin, glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) secretion by octreotide has no effect on post-heparin plasma lipoprotein lipase activity
I welcome hearing from you
GLP-1 receptor agonist peptides are synthetic compounds designed to replicate or enhance the effects of glucagon-like peptide-1 (GLP-1), an incretin hormone released by the gut after eating
Commenting on their vision, the Co-Founder and Managing Partner of Corridor Ventures, Kwamena Aidoo, commented that Connecting wearable device and electronic health records data has the potential to transform clinical research insights and evolve the way health and wellness care is administered across the globe. They continue, suggesting that Patientory sits at the forefront of this movement
Evidence and rationale Current guidelines do not address GLP-1 RAs in the inpatient setting
GLP-1 also regulates gastric motility by slowing gastric emptying in a dose-dependent manner, helping to control postprandial glucose levels